FADS2 and dermatitis: The IL‐23 intradermal injection model more closely recapulates the IL‐23/Th17‐driven immune axis in human psoriasis and has shown strong predictive value for biologic therapies targeting this axis.[61, 62] Humanized xenograft models further offer an in vivo platform to study human skin inflammation and treatment responses, preserving the structural and immunological features of human skin.[63, 64] These models may provide useful avenues for future validation of the PPARα–FADS2 signaling pathway in psoriasis.